Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes
dc.contributor.author | Braunwald, Eugene | en_US |
dc.contributor.author | Angiolillo, Dominick | en_US |
dc.contributor.author | Bates, Eric R. | en_US |
dc.contributor.author | Berger, Peter B. | en_US |
dc.contributor.author | Bhatt, Deepak | en_US |
dc.contributor.author | Cannon, Christopher P. | en_US |
dc.contributor.author | Furman, Mark I. | en_US |
dc.contributor.author | Gurba, Paul E. | en_US |
dc.contributor.author | Michelson, Alan D. | en_US |
dc.contributor.author | Peterson, Eric | en_US |
dc.contributor.author | Wiviott, Stephen | en_US |
dc.date.accessioned | 2008-05-12T13:36:01Z | |
dc.date.available | 2009-03-04T14:20:46Z | en_US |
dc.date.issued | 2008-03 | en_US |
dc.identifier.citation | Braunwald, Eugene; Angiolillo, Dominick; Bates, Eric; Berger, Peter B.; Bhatt, Deepak; Cannon, Christopher P.; Furman, Mark I.; Gurbel, Paul; Michelson, Alan D.; Peterson, Eric; Wiviott, Stephen (2008). "Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes." Clinical Cardiology 31(S1): I-2-I-9. <http://hdl.handle.net/2027.42/58556> | en_US |
dc.identifier.issn | 0160-9289 | en_US |
dc.identifier.issn | 1932-8737 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58556 | |
dc.description.abstract | Numerous clinical trials have established the value of antiplatelet therapies for acute coronary syndromes (ACS). Aspirin (ASA), thienopyridines (i.e., clopidogrel and ticlopidine) and GP IIb/IIIa antagonists comprise the major classes of antiplatelet therapies demonstrated to be of benefit in the treatment of ACS and for the prevention of thrombotic complications of percutaneous coronary intervention (PCI). Clopidogrel is beneficial when administered before and after PCI, and is more effective when combined with either ASA or GP IIb/IIIa inhibitors in preventing post-PCI complications, coronary subacute stent thrombosis, and thrombotic events in general. It is currently unclear whether a higher loading dose of clopidogrel (600 mg) is better than the standard loading dose (300 mg), how long therapy should continue, and which maintenance dose is optimal. The role of the GP IIb/IIIa antagonists in ACS is less clear due to conflicting data from several studies with different patient populations. Currently, it appears that the use of GP IIb/IIIa antagonists might be most beneficial in high-risk ACS patients scheduled to undergo PCI, who demonstrate non-ST-segment elevation myocardial infarction and elevated troponin levels. Copyright © 2008 Wiley Periodicals, Inc. | en_US |
dc.format.extent | 383469 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Medicine and Healthcare | en_US |
dc.subject.other | Cardiovascular Disease | en_US |
dc.title | Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialities | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; | en_US |
dc.contributor.affiliationother | TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; ; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, University of Florida College of Medicine, Jacksonville, Florida; | en_US |
dc.contributor.affiliationother | Geisinger Center for Health Research, Danville, Pennsylvania; | en_US |
dc.contributor.affiliationother | Department of Cardiovascular Medicine, Cardiovascular Coordinating Center, Cleveland Clinic, Cleveland, Ohio; | en_US |
dc.contributor.affiliationother | TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; | en_US |
dc.contributor.affiliationother | Cardiovascular Medicine, South Shore Hospital, South Weymouth, Massachusetts; | en_US |
dc.contributor.affiliationother | Department of Medicine, Sinai Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland; | en_US |
dc.contributor.affiliationother | Center for Platelet Function Studies, Pediatrics, Medicine, and Pathology, University of Massachusetts Medical School, Worcester, Massachusetts; | en_US |
dc.contributor.affiliationother | Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA | en_US |
dc.contributor.affiliationother | TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58556/1/20362_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/clc.20362 | en_US |
dc.identifier.source | Clinical Cardiology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.